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A prediction model for underestimation of invasive breast
cancer after a biopsy diagnosis of ductal carcinoma in situ:
based on 2892 biopsies and 589 invasive cancers
Claudia J. C. Meurs1, Joost van Rosmalen2, Marian B. E. Menke-Pluijmers3, Bert P. M. ter Braak4, Linda de Munck5, Sabine Siesling5 and
Pieter J. Westenend6,7
BACKGROUND: Patients with a biopsy diagnosis of ductal carcinoma in situ (DCIS) might be diagnosed with invasive breast cancer
at excision, a phenomenon known as underestimation. Patients with DCIS are treated based on the risk of underestimation or
progression to invasive cancer. The aim of our study was to expand the knowledge on underestimation and to develop a prediction
model.
METHODS: Population-based data were retrieved from the Dutch Pathology Registry and the Netherlands Cancer Registry for DCIS
between January 2011 and June 2012.
RESULTS: Of 2892 DCIS biopsies, 21% were underestimated invasive breast cancers. In multivariable analysis, risk factors were high-
grade DCIS (odds ratio (OR) 1.43, 95% conﬁdence interval (CI): 1.05–1.95), a palpable tumour (OR 2.22, 95% CI: 1.76–2.81), a BI-RADS
(Breast Imaging Reporting and Data System) score 5 (OR 2.36, 95% CI: 1.80–3.09) and a suspected invasive component at biopsy (OR
3.84, 95% CI: 2.69–5.46). The predicted risk for underestimation ranged from 9.5 to 80.2%, with a median of 14.7%. Of the 596
invasive cancers, 39% had unfavourable features.
CONCLUSIONS: The risk for an underestimated diagnosis of invasive breast cancer after a biopsy diagnosis of DCIS is considerable.
With our prediction model, the individual risk of underestimation can be calculated based on routinely available preoperatively
known risk factors (https://www.evidencio.com/models/show/1074).
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BACKGROUND
Patients with ductal carcinoma in situ (DCIS) are treated based on
the risk of underestimation or progression to invasive cancer. The
standard treatment for patients with a biopsy diagnosis of DCIS is
wide local excision with radiation or mastectomy. Often a sentinel
lymph node (SLN) biopsy is advised for axillary staging.1,2 Both the
standard treatment and the use of the SLN biopsy can constitute
overtreatment. The standard treatment might be disproportionate
for screen-detected DCIS patients who have a high chance that
the DCIS would not even have been detected during their
lifetime.3 It has been estimated that between 14 and 53% of DCIS
progress into invasive breast cancer.4,5
To address overtreatment, phase III trials investigate the safety
of active surveillance of DCIS patients at low risk for developing or
having invasive breast cancer.6–11 Active surveillance is based on
the result of the biopsy. By modelling of active surveillance of DCIS
patients, the disease-speciﬁc cumulative mortality was related to
underestimation.12,13 Underestimation is the phenomenon that
the invasive breast cancer is undetected at preoperative biopsy
and only becomes evident after pathological examination of the
excision material. The use of the SLN biopsy can also constitute
overtreatment. The SLN biopsy is done if a mastectomy is chosen,
and also for patients undergoing wide local excision who are at
high risk of having an underestimated invasive breast cancer.1,2
The reported risk of underestimation varies from 14 to 43%14,15,
and in a meta-analysis it was estimated to be 25.9% (95%
conﬁdence interval (CI): 22.5–29.5)16. These rates indicate that
many patients will still have the diagnosis of DCIS after
examination of the excision material, and thus the SLN biopsy
would not have been necessary.
Knowledge on the risk of underestimation is important in
selecting high-risk or low-risk patients for treatment or active
surveillance. The most frequently reported risk factors for under-
estimation are DCIS grade and factors found with radiological
diagnostic work-up, such as the size of the lesion, mass on
mammography or ultrasonography, and the Breast Imaging
Reporting and Data System (BI-RADS) score.14–27 Furthermore,
these studies reported that the risk of underestimation was
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associated with age, palpability, histologic suspicion of invasion,
image guidance method, biopsy device and other factors. An
overview of the found risk factors for underestimation is given in
Table 1. Based on risk factors, several studies developed prediction
models with the purpose to select patients for SLN
biopsy14,17,24,28–30.
Besides the underestimation rate, other factors are useful for
making a treatment plan for a patient diagnosed at biopsy with
DCIS. First of all, for some of these patients, no residual disease is
found in the excision material; this is deﬁned as minimal-volume
DCIS. A rate of 9.3% was reported.31 Second, of the under-
estimated invasive breast cancers the information on unfavour-
able features is of interest; the reported Her2Neu status is quite
high22,23 and the hormonal receptor statuses vary21–23,25,26.
The diversity of identiﬁed risk factors for underestimation has
resulted in differences between the clinical guidelines used in
different countries. For example, according to the NICE guideline
(United Kingdom) for the use of the SLN biopsy, risk factors for
Table 1. Results of previous studies on risk factors for underestimation
Variablesa,b Signiﬁcance of potential risk factors, as described in literaturec,d
No Yes, univariablee Yes, multivariablef
Age 15, 16, 18, 22, 24, 25 14, 21
Detection modeg 14, 16
Palpable 22 16 15, 18, 23/28, 24, 25, 26
Clinical size of mass 18
BI-RADSg 21, 23 14, 15, 16
Maximum size on imaging 16 22
Maximum size on mammographyg 18, 21, 26 14, 20, 24, 25
Maximum size on ultrasonographyg 23 15, 30
Maximum size on MRI 26 30
Mass on imaging 14
Mass on mammography 16, 26 18
Mass on ultrasonography 30 26 23/28
Visibility on ultrasonography 16 24
Type of mammographic abnormalityg 14, 21, 24 15 25
Calciﬁcations on mammography 23, 26 30
Calciﬁcations on ultrasonography 23/28
Suspicious ﬁndings on ultrasonography or MRI 30
Multicentric 14
Breast density 14
Residual disease on mammogram after biopsy 21
Calciﬁcation % removed by CNB 14
Biopsy guidance techniqueg 14, 16, 24, 26
Biopsy type CNB, VAB 24 16, 25 15, 22, 23/28
Biopsy needle gauge 14
Number of cores obtainedg 14, 21 15, 25, 26
DCIS grade 26 16, 23, 24, 25 14, 15, 20
Nuclear grade 26, 30 22
Suspicious of invasion on biopsy 23/28, 24
Comedo-necrosis 16, 18, 23, 26 14, 22, 25 30
Intraductal structure 25
Cibriform 14 22
Sclerosing adenosis 30
Hormone receptor ER/PR 22
Progesterone receptor 30
HER2 22 30
aVariables in bold are variables that were analysed in this study
bVariables that were analysed but were not statistically signiﬁcant in any study were: mass on MRI (30), mass on ultrasonography or MRI (30), abnormality on
mammography; mass, asymmetry or distortion (23), calciﬁcations on imaging (22), suspicious ﬁndings on ultrasonography (30), suspicious ﬁndings on MRI
(30), solid (14, 22) papillary (14, 22), micropapillary (14, 22), necrosis (22), oestrogen receptor (14,30), period from breast biopsy to surgery (25), Van Nuys
grouping (23), family history (21), menopausal status (21) and type of ﬁrst resection (18)
cListed are 12 studies with at least 100 cases of underestimation
dReferences in bold are of the ﬁve studies that developed a prediction model
eReference 16 presents results of random-effect logistic regression models in a meta-analysis
fThe multivariable signiﬁcant variables of ref. 23 were used in a prediction model, as described in ref. 28
gThe categories of these variables were not uniformly deﬁned between studies
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underestimation are a palpable mass or extensive micro-calciﬁca-
tions, while according to the Dutch guideline, these are age <55
years, intermediate-grade or high-grade DCIS, a mass on
mammography and a suspected invasive component based on
biopsy. For active surveillance, the main criterion for patient
selection in low-risk DCIS trials are DCIS grade, and patients with
mass or other relevant factors are excluded.
The diversity in risk factors might be due to the study designs,
since the investigated potential risk factors varied and many
studies on underestimation were single institution studies with
limited number of cases. Information at the population level is
lacking. In addition, there is hardly any data on minimal-volume
DCIS nor on the presence of unfavourable features of the
underestimated invasive breast cancer.
The aim of our study was to expand the knowledge on
underestimation of invasive breast cancer for patients with a
biopsy diagnosis of DCIS in routine clinical practice in the
Netherlands and to develop a prediction model based on
population data. We also analysed the association of predicted
risk with minimal-volume DCIS and with the occurrence of
unfavourable features of the underestimated invasive breast
cancer. The results could contribute to a treatment plan that is
both patient-speciﬁc and helps in reducing overtreatment.
METHODS
Study design and population
This study used retrospective data that were nationwide. Data
were received from the Dutch Pathology Registry, which is
managed by PALGA (the nationwide network and registry of
histopathology and cytopathology in the Netherlands) and were
matched with data from the Netherlands Cancer Registry (NCR),
which is hosted by the IKNL (the Netherlands Comprehensive
Cancer Organization). The Dutch Pathology Registry contains all
the reports written by pathologists of material examined in all
Dutch Pathology Laboratories.32 The NCR contains information
that is collected and coded by specially trained registration clerks
from the hospitals’ patient ﬁles of every patient with cancer, after
notiﬁcation from PALGA.33
Lesions were selected from PALGA, since this study is based on
the biopsy diagnosis and the NCR registers the ﬁnal diagnosis at
excision. Histological breast biopsies were selected that were
performed in the period 1 January 2011 until 30 June 2012. The
diagnosis should be carcinoma in situ, with no invasive cancer in
the same biopsy, no lymph node metastases found preoperative
and also no melanoma in situ, Morbus Paget or Morbus Bowen.
DCIS with micro-invasion was not included, nor were intracystic
carcinoma, lobular carcinoma in situ and ductal hyperplasia
lesions. Based on the PALGA conclusion (free text ﬁeld) informa-
tion on the diagnosis, DCIS grade, suspected invasive component,
synchronous contralateral tumour and ipsilateral history were
coded. The data were extended with those registered by the NCR:
age, ipsilateral history, detection mode, palpability, BI-RADS score,
preoperative magnetic resonance imaging (MRI), multidisciplinary
team meeting, type of ﬁrst resection, nodal status, and of the
invasive cancers, the morphology, grade, the receptors ER, PR,
Her2Neu and tumour size. Lesions were excluded in case of
incomplete registration, primarily no excision of the lesion, a
biopsy diagnosis that was inconclusive as to whether the lesion
was benign or DCIS and in case of an ipsilateral history of DCIS or
invasive breast cancer.
Data were categorized as follows: the category detection mode
consisted of screen-detected DCIS (DCIS detected within
12 months after a positive mammography at the population-
based screening programme) and otherwise detected DCIS (all
other DCIS). DCIS grade was categorized into low, intermediate or
high. If the tumour consisted of two different grades or if the
grade was inconclusive, the highest DCIS grade was chosen.
Suspected invasive component was coded ‘yes’ if it was
mentioned as such in the conclusion of the pathology report
and if it was not refuted with potential additional staining. For the
BI-RADS score, no subgroup information for score 4 was
available.34 A synchronous contralateral lesion was deﬁned as
DCIS or invasive breast cancer in both breasts with a difference in
incidence date of <3 months. Underestimation was deﬁned as
invasive cancer or micro-invasion found at excision after a biopsy
diagnosis DCIS. Tumours were graded according to the
Bloom–Richardson grade or another equivalent method. Tumour
size and nodal status were used to categorize the tumor node
metastasis (TNM) stage.35 Underestimated invasive breast cancers
were categorized based on unfavourable features. In the Dutch
guideline36, they were deﬁned as features that, if present, would
mean that systemic therapy would be recommended, because the
absolute 10-year mortality risk was at least 15%. These features of
the invasive cancers were:
● Her2Neu positive with size >5mm.
● Age <35 years, except size ≤10mm with grade I.
● Size >10mm but ≤20mm with grade II or III.
● Size >20mm.
● Positive lymph nodes.
Statistical analysis
The data were analysed to investigate associations and to develop
a prediction model. First, the distribution of patient characteristics
and potential risk factors was compared between patients with
and without underestimated invasive breast cancer for the non-
missing values, using the Mann–Whitney test or the Pearson's χ2
test. The associations between potential risk factors were analysed
with the Pearson's χ2 test or the Fisher's exact test. The risk for
underestimation of invasive breast cancer was analysed with
logistic regression analysis. The threshold for signiﬁcance of risk
factors was the two-sided p value of 0.05. In this logistic
regression, we only included characteristics that were known as
independent variables prior to operation: age, detection mode,
palpability, BI-RADS score, DCIS grade and suspected invasive
component at biopsy. The decision to do a preoperative MRI and
the type of ﬁrst resection were not included in the model, because
no causal association with underestimation was expected. Next, to
ensure that all relevant variables were included in the prediction
model, the independent variables were chosen via stepwise
backward selection with a p value threshold for elimination of p <
0.20. In the prediction model, age was tested multiple times:
continuously using both linear and quadratic terms and dichot-
omously with thresholds of 40, 45 and 55 years for comparison
with previous publications.1,6,21 Interaction was tested for
combinations that were clinically the most plausible: suspected
invasive component and DCIS grade, age <45 years (based on cut-
off age in active surveillance) in combination with BI-RADS score,
or palpability, or DCIS grade. To account for missing data, multiple
imputation with fully conditional speciﬁcation was used in the
multivariable logistic analysis. Twenty imputed data sets were
generated, and the results were pooled according to Rubin’s rules.
Based on the imputed data, a formula was deﬁned to predict the
risk. Finally, internal validation of the model was performed with
bootstrap repetitions (200 times). The logistic regression model
was evaluated with the area under the curve (AUC) of the receiver
operating characteristic (ROC). Based on the predicted risks,
patients were divided into ﬁve subgroups, and the association
with minimal-volume DCIS and unfavourable features was
analysed with the p-trend test for proportions. The analyses were
done with STATA statistics/data analysis, version 13.1, StataCorp,
Texas and in R, with the rms package for the evaluation of the
predictive performance and the mice package for multiple
imputation.
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RESULTS
Of 3281 lesions that were selected with a preoperative biopsy
diagnosis DCIS, 64 (2.0%) were excluded because they were not
registered in the NCR, and 15 (0.5%) because registration was
incomplete. In addition, to answer the research question
accurately, more were excluded: 60 (1.8%) that did primarily not
undergo excision, 143 (4.4%) for which the biopsy diagnosis was
inconclusive and 107 (3.3%) with an ipsilateral history of DCIS or
invasive breast cancer, resulting in 2892 DCIS diagnoses included
in the study. Of these, 379 (13%) had missing data for one or more
potential risk factor: 148 for palpability, 223 for BI-RADS score, 84
for DCIS grade and 81 for detection mode.
Of the 2892 DCIS diagnoses at biopsy, 596 (20.6%) were
underestimated, as the diagnosis was invasive breast cancer at
excision. Table 2 shows patient and biopsy characteristics and
their relation with underestimation. Of biopsy DCIS, 66% was
screen detected, 22% was palpable, 13% had a BI-RADS score 3,
75% had a BI-RADS score 4, 12% had a BI-RADS score 5 and 5%
had a suspected invasive component at biopsy. The DCIS grade
distribution was 15% low, 39% intermediate and 46% high (p=
0.001). Of the intermediates, 13% were low to intermediate or
consisted of both low-grade and intermediate-grade DCIS, 21%
were intermediate to high grade or consisted of both
intermediate-grade and high-grade DCIS. The underestimation
rate was 21% on average for all cases, 26% for non-screen-
detected lesions, 36% for palpable lesions, 41% for BI-RADS score
5 and 23% for high-grade DCIS (p values between different
categories were <0.001 for all variables). The risk factors with the
greatest differences in underestimation rate for subgroups were
palpability, with a 20% higher rate for palpable than for non-
palpable lesions, BI-RADS score, with a 25% higher rate for BI-
RADS score 5 than for score 3, and suspected invasive component,
with a 31% higher rate for suspected invasive component than for
none. Of 596 invasive breast cancers, 47 were T1mi and 207 were
T1a. The underestimation rate when ﬁltering out all lesions of
5 mm or smaller was 11.8% (n= 342).
Table 3 shows the results of univariable and multivariable
analysis of the risk for underestimation of preoperatively known
potential risk factors for invasive breast cancer. Age and detection
mode were statistically signiﬁcant in univariable analysis, but not
in multivariable analysis. Both were associated with palpability and
BI-RADS score, and age was also associated with DCIS grade
(shown in supplement 1, along with other associations). In
multivariable analysis, grade, palpability, BI-RADS score and a
suspected component were signiﬁcant.
For each of the 2892 DCIS, the risk of an underestimated
invasive breast cancer was calculated based on the prediction
model with the following formula:
Predicted risk ¼ 1
1þ escore
 
´ 100%;
with score=−2.1131+ 0.1555 × detection_mode_otherwise+
0.7985 × palpable− 0.1464 × BI-RADS_score_3+ 0.8589 × BI-
RADS_score_5+ 0.3111 × intermediate_DCIS_grade+ 0.3571 ×
high_DCIS_grade+ 1.3445 × suspected_invasive_component,
where for all risk factors: 1= if condition applies, 0= otherwise.
For example, the predicted risk is calculated as follows for a
screen-detected DCIS which is non-palpable, has a BI-RADS score
4, an intermediate-grade and no suspected invasive component:
score=−2.1131+ 0.1555 × 0+ 0.7985 × 0− 0.1464 × 0+
0.8589 × 0+ 0.3111 × 1+ 0.3571 × 0+ 1.3445 × 0=−1.802, and
Predicted risk ¼ 1
1þ eð1:802Þ
 
´ 100% ¼ 14:2%:
The risk for an individual patient can be calculated in a user-
friendly way with a calculation tool in Evidencio, https://www.
evidencio.com/models/show/1074.
The predicted risks ranged from 9.5 to 80.2%, the mean was
20.6% and the median was 14.7%. The predicted risk for
Table 2. Distribution of underestimation rate
All Underestimated invasive
breast cancer
p value
No Yes
N N % N %
Total 2892 2296 79.4% 596 20.6%
Age (years), mean
(range)
58.7
(24–91)
58.9 (30–88) 57.8 (24–91) 0.033
Age categories <0.001
<45 years 207 142 69% 65 31%
≥45 years 2685 2154 80% 531 20%
Detection mode <0.001
Screen detected 1850 1521 82% 329 18%
Otherwise 961 714 74% 247 26%
Missing 81 61 75% 20 25%
Palpable <0.001
No 2147 1794 84% 353 16%
Yes 597 380 64% 217 36%
Missing 148 122 82% 26 18%
BI-RADS score <0.001
3 365 306 84% 59 16%
4 1996 1638 82% 358 18%
5 308 183 59% 125 41%
Missing 223 169 76% 54 24%
DCIS histological grade
at biopsy
0.001
Low 422 360 85% 62 15%
Intermediate 1083 866 80% 217 20%
High 1303 1006 77% 297 23%
Missing 84 64 76% 20 24%
Suspected invasive
component at biopsy
<0.001
No 2743 2222 81% 521 19%
Yes 149 74 50% 75 50%
Synchronous
contralateral breast
tumour
0.181
No 2796 2225 80% 571 20%
Yes 96 71 74% 25 26%
Preoperative MRI <0.001
No (or unknown) 2188 1773 81% 415 19%
Yes 704 523 74% 181 26%
Preoperative
multidisciplinary team
meeting
0.364
No (or unknown) 301 245 81% 56 19%
Yes 2591 2051 79% 540 21%
First resection <0.001
Wide local excision 1822 1510 83% 312 17%
Mastectomy 1070 786 73% 284 27%
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underestimation was on average 27.4% for the biopsy of DCIS that
were underestimated invasive breast cancers, whereas it was on
average 18.8% for the biopsy of DCIS that also had the DCIS
diagnosis at excision. The predicted risks for each combination of
risk factors are shown in supplement 2. The matching of the
predicted risks with the observed rate is shown in supplement 3.
The ability of the model to separate DCIS as diagnosis after
excision from underestimated invasive breast cancer is shown in
Fig. 1. To draw this ﬁgure, the DCIS were divided into low-risk or
high-risk DCIS based on a cut-off point, and for each point the
sensitivity and 1-speciﬁcty was calculated. In this study, the
sensitivity means the rate of underestimated invasive breast
cancer that was correctly predicted as high risk, and 1-speciﬁcity
means the rate of DCIS at excision that was falsely predicted as
high risk. The AUC (c-index) of the ROC was 0.668 and the AUC,
corrected for optimism by bootstrapping, was 0.661. The AUC for a
model based only on lesions >5mm was 0.69.
Based on the predicted risks, the DCIS biopsies were divided
into ﬁve subgroups; the characteristics of each subgroup are
shown in Table 4. From the subgroups with the lowest predicted
risk to the subgroup with the highest predicted risk, the
underestimation rate increased from 10.7 to 40.1%.
The associations between the predicted risks and minimal-
volume DCIS were as follows: the rates of minimal-volume DCIS
decreased from 18.0 to 1.6% from the subgroups with the lowest
predicted risk to the subgroup with the highest predicted risk, p <
0.001 (see Table 4). On average, 6.8% of DCIS diagnoses at biopsy
were minimal-volume DCIS, in which the DCIS was completely
removed via biopsy (meaning 8.5% of the 2296 lesions with the
DCIS diagnosis at excision).
The associations between the predicted risks and unfavourable
features were as follows: the percentage of invasive breast cancers
with unfavourable features increased from 15.9 to 49.5% from the
lowest to the highest predicted risk group, p < 0.001 (see Table 4).
On average, 39% of the invasive breast cancers had unfavourable
features. More details on the distribution of tumour characteristics
of the 596 invasive breast cancers are shown in supplement 4. Of
the invasive breast cancers, 27% were grade III, 26% were
Her2Neu positive, 8% were triple negative, 77% were TNM stage
1A (size at maximum 2.0 cm and no metastasis) and the median
size was 6 mm.
DISCUSSION
The aim of our study was to expand the knowledge on
underestimation of invasive breast cancer at core-needle biopsy
in the routine clinical practice in the Netherlands and to develop a
prediction model based on the analysis of a retrospective
population-based dataset of 2892 DCIS diagnoses. We also
analysed the association of predicted risk with minimal-volume
DCIS and with the occurrence of unfavourable features of the
underestimated invasive breast cancer.
The risk for underestimation of invasive breast cancer after a
DCIS diagnosis was almost 21%. Preoperatively known risk factors
for an underestimated diagnosis of invasive breast cancer were a
high DCIS grade, a palpable tumour, a BI-RADS score 5 and a
histologically suspected invasive component. Detection mode was
also included in the model, although the association with
underestimation was comparably weak. The predicted risk for
underestimation ranged from 9.5 to 80.2%. Of the 596 under-
estimated invasive breast cancers, 39% had unfavourable features.
Of the DCIS diagnoses at excisional pathology, 6.8% were
minimal-volume DCIS.
Table 3. Risk factors for underestimation
Preoperative
patient and
lesion
characteristicsa
Logistic regression analysis for underestimation of
invasive breast cancer
Univariable Multivariableb
OR 95% CI p value OR 95% CI p value
Age (years) not in
the
modelc
<45 1.86 1.34–2.53 <0.001
≥45 1
Detection mode
Screen detected 1 1
Otherwise 1.60 1.33–1.93 <0.001 1.16 0.94–1.45 0.164
Palpable
No 1 1
Yes 2.90 2.37–3.55 <0.001 2.22 1.76–2.81 <0.001
BI-RADS score <0.001 <0.001
3 0.88 0.65–1.19 0.487 0.86 0.64–1.17 0.348
4 1 1
5 3.13 2.43–4.03 <0.001 2.36 1.80–3.09 <0.001
DCIS histological
grade at biopsy
0.001 0.078
Low 1 1
Intermediate 1.45 1.06–1.98 0.017 1.36 0.99–1.87 0.054
High 1.71 1.27–2.31 <0.001 1.43 1.05–1.95 0.025
Suspected invasive component biopsy
No 1 1
Yes 4.32 3.09–6.04 <0.001 3.84 2.69–5.46 <0.001
aFor all interaction variables p > 0.05: grade and suspect, p= 0.469, age <45
years; palpable, p= 0.168, age <45 years; BI-RADS, p= 0.996, age <45 years;
DCIS grade, p= 0.108
bBased on the imputed dataset
cAge: continuous: p= 0.552, quadratic relationship (adding a quadratic
term): p= 0.257, dichotomous with threshold 40 years: p= 0.923,
dichotomous with threshold 45 years: p= 0.421, dichotomous with
threshold 55 years: p= 0.644
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Fig. 1 Performance of the model in relation to the chosen cut-off
point of the predicted risks
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The underestimation rate of 20.6% shows that excision of the
DCIS is still not only important for preventing DCIS from
progressing to invasive breast cancer but also for ﬁnding already
existing invasive breast cancers. The rate found in our study was in
between the 25.9% of a meta-analysis published in 2011 and the
recently reported 14.1% of a large single institution study.14,16 The
underestimation rate is associated with the diagnostic work-up
whereby there is a tendency to decreasing underestimation rates
in more recent time period. This study used data from 2011 and
2012. At that time vacuum-assisted biopsy was not yet commonly
used in the Netherlands, therefore we assume that the under-
estimation rate currently will be somewhat lower in the Nether-
lands. And in the period 2011–2012, hospitals often used screen
ﬁlm mammography, but the screening mammography was
already digitized, and therefore no major difference in under-
estimation rate. The Netherlands currently is assumed because of
this change in technique.
This population-based study showed several clinical, radiologi-
cal and pathological features that are all routinely available before
operation as risk factors for underestimation.
The risk factors we found are partly similar to those reported in
literature. Differences could be due to sample size, as this study
was much larger than other studies: studies in literature had 172
to 834 cases and up to 145 events, whereas we had 2892 cases
and 589 events. Differences in study outcomes could also be
caused by the combination of available data and the correlation
between many data. For age, others found various risks for the
youngest age category: no increase25, increased but not
signiﬁcantly so16 and univariable signiﬁcant but not in multi-
variable analysis14,21. In our study, young age was also only
univariably associated with underestimation. For DCIS grade, the
risk of underestimation for intermediate grade was in between the
risk for low-grade and high-grade DCIS. This was also reported by
some other studies14,20,27, whereas others reported the risk for
intermediate-grade DCIS as comparable to that of the high-grade
risk19,25. In our study the DCIS grade was less discriminative than
the other risk factors in the model, but on the other hand the
underestimation rate of 15% for low DCIS grade was the lowest
rate for a subgroup in the model and high grade was the largest
subgroup with an increased risk. Palpability of the lesion has
consistently been reported as a risk factor, which this study could
conﬁrm.15,16,18,19,22–24,26,37 The BI-RADS score is an assessment
categorization that should give an indication of the likelihood of
cancer based on the interpretation of the radiologist. We showed
that it is associated with the underestimation rate; the difference
between BI-RADS score 4 and 5 was 23% in underestimation rate,
which is much larger than the 7–8% found by others.16,21 A larger
difference was reported in a study with a high average
underestimation rate due to a high rate of micro-invasion.15 Still,
the study of Kim et al.15 is interesting because they found a
somewhat higher underestimation rate for BI-RADS score 4c,
compared to 4a and 4b. It is worth noting that the BI-RADS score
has not yet been investigated very extensively. A suspected
invasive component has also only been reported in a limited
number of studies.23,24; all found a high risk for underestimation
for biopsies with a suspected component.
The prediction model we developed with the identiﬁed risk
factors must be used wisely. For selecting high-risk lesions, it has
to be noted that lesions with a high predicted risk still have a
good chance of a ﬁnal diagnosis of DCIS since the sensitivity of the
model was low. The sensitivity or the AUC was higher in several
other studies.14,17,22,24,28 Each study with a prediction model used
different risk factors and therefore the models are not easily
comparable. This has also been demonstrated in external
validation of studies that applied published models to their cases;
one study demonstrated a tendency towards lower or higher
numbers of observed underestimates than expected29, and
another previous study demonstrated validation AUCs ofT
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0.59–0.66, whereas the studies they validated reported validities of
0.70–0.8514. The low AUC in this study could also be due to the
absence of certain data that might have been important, such as
the type of biopsy device and the size of the lesion on
mammography. This is shown in Table 1, where the references
that were made bold are the results of the studies making a
prediction model, whereas the variable names that are given in
bold are the variables that were analysed in this study.
Part of the DCIS was minimal-volume DCIS and was thus
removed from the biopsy itself. In this study, minimal-volume DCIS
was associated with the predicted underestimation risk. To our
knowledge, this information has never been demonstrated before;
one study demonstrated a similar rate of minimal-volume DCIS,
but the association with underestimation was not investigated.31
In our study, the minimal-volume DCIS was higher for the
predicted low-risk group.
The invasive breast tumours that were found at excision were
heterogeneous in prognostic and predictive features. Under-
estimated invasive tumours are often small: the median size was 6
mm, which is in line with or somewhat lower than the results of
other studies.17,25–27 On the other hand, 8% were TNM stage IIB or
III, and 20% were triple negative or ER-PR-Her2Neu+. Where other
studies analysed none or a few tumour characteristics, we had
numerous tumour-related data of the 589 underestimates. Based
on these data, we calculated the rate of cancers with unfavourable
features, which was 39%. For these patients, systemic therapy was
indicated. In our study, the rate of unfavourable features was
higher for the predicted high-risk DCIS group.
Due to its retrospective nature, this study has certain limitations.
A limitation in interpreting the results is that the preoperative
decisions and techniques were not standardized, and therefore
the preferences of the treating physicians and the patients will
have inﬂuenced the underestimation results. For instance, for a
high-grade DCIS with histological suspicion of invasiveness, the
biopsy can be repeated (and invasive breast cancer might be
found preoperatively) or initial treatment can be started (with an
increased risk of underestimation). Also, for DCIS grade, other
studies might have used different grading systems. Another
limitation is that results of observational studies are difﬁcult to
compare because of differences in diagnostic work-up, differences
in major selection criteria, such as the presence of micro-invasion,
differences in investigated risk factors and associations between
the investigated risk factors. Our dataset did not provide
information on the number of biopsies nor on the biopsy device,
and hence the amount of tumour taken at biopsy was not known.
Some other factors were not available either, such as the presence
of comedo-necrosis, the breast density, the visibility of the lesion
on ultrasound, the presence of mammographic mass or the size of
the lesion seen on the mammogram.
The model in this study is based on a large dataset that is based
on nationwide Dutch data, and it demonstrated the association of
risk for underestimation with minimal-volume DCIS and unfavour-
able features of invasive cancer, which makes the results valuable.
The prediction model could be improved by adding additional
data; the most interesting targets of investigation for future
research are the biopsy type and mammography-related data: BI-
RADS score 4 subcategories, the underlying reasons for a BI-RADS
score (such as mass), size of the lesion and presence of residual
mammographic abnormalities after biopsy. Furthermore, the
prediction model should be validated externally.
CONCLUSION
Our results demonstrated that the risk for an underestimated
diagnosis of invasive breast cancer after a diagnosis of DCIS at
biopsy is considerable. Of these invasive breast cancers, two-ﬁfths
has unfavourable features. With our prediction model, the
individual risk of underestimation can be calculated based on
routinely available preoperatively known risk factors
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